Exploration of hypoglycemic effect of an extract from leaves of a plant from Tunisian pharmacopeia: artemisia campestris (asteraceae) by Belgacem, Amel et al.
Exploration of  hypoglycemic effect of  an extract from leaves of  a plant from Tunisian 
pharmacopeia: Artemisia campestris (Asteraceae)
Amel Belgacem, Neyla Ben Gdara, Ikram Khemiri, Lotfi Bitri
Department of  Biology, University of  Tunis El Manar, Faculty of  Sciences of  Tunis, University campus 2092, 
El Manar, Tunis, Tunisia.
 
Emails:
Neyla Ben Gdara: neylabengdara@yahoo.fr, Ikram Khemiri: ikramkhemiri@gmail.com, Lotfi Bitri: bitrilotfi@yahoo.
fr
Abstract
Background and objectives: A lot of  research has been directed towards medicinal plants which are considered as a source 
of  multiple phytotherapic substances endowed with hypoglycemic activities that could be used to treat diabetes and its compli-
cations. Our study was carried out in Wistar rats to investigate the hypoglycemic effect of  n-Butanol Fraction from Artemisia 
campestris leaf  Methanolic Extract (BFACME).
Methods: Two experimental models were used in rats: orally induced hyperglycemia (OGTT) and isolated perfused liver (IPRL).
Results: BFACME at 550 mg/kg BW dose significantly reduced fasting glucose level in normal rats as compared to controls. 
The decrease of  glycaemia was 12.6% more significant than that obtained with the standard drug glibenclamide (10 mg/kg BW), 
an oral antidiabetic preparation belonging to sulfonylurea class. In OGTT model, BFACME at the highest doses of  550 and 
400 mg/kg BW significantly reduced the postprandial hyperglycemic peak compared to controls. In the IPRL model, treatment 
with BFACME significantly decreased glucose concentrations after 30 min of  perfusion with 30 mM glucose solely when insulin 
was present. The higher doses of  BFACME lead to glucose concentration at basal level as early as 90 min, while the lowest dose 
does not restore this concentration even to t = 120min. The best initial glucose concentration retrieval was obtained with 0.7 
mg BFACME/mL/g liver. At this dose, BFACME improves the decrease of  glucose level caused by only insulin by about 18%.
Conclusion: The BFACME appears to exert a hypoglycemic activity by potentiating the insulin action. 
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Introduction
Diabetes mellitus is a polygenic metabolic disorder char-
acterized by chronic hyperglycemia, resulting from a de-
fect in insulin secretion or insulin action or both associ-
ated anomalies1. This chronic hyperglycemia is associated 
to long-term complications, affecting especially eyes, kid-
neys, nerves, heart and blood vessels2. According to the 
International Diabetes Federation, 285 million people 
around the world had diabetes in 2010, about 6.6% of  the 
planet's adult population3. The number of  people with 
diabetes is projected to rise from 366 million in 2011 to 
almost 552 million in 20304. Tunisia ranks low in terms 
of  diabetes management, which would be the cause of  
8.1% of  deaths in women and 5.7% among men5,6. Due 
to the spread of  this chronic disease, the World Health 
Organization encouraged ethnobotanical studies and 
pharmaceutical researches to improve the effect of  herb-
al medicinal products, in order to promote optimal use in 
the health care delivery systems. Plants continue to be of  
great interest despite the development of  the synthetic 
based pharmaceutical industry/span>7. The use of  plants 
to treat chronic diseases is a part of  an ancient Tunisian 
tradition. Artemisia campestris of  the Asteraceae family is 
one of  plants used in various recipes to cure multiple 
health issues in north Africa8,9. This species, known as 
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“Tgouft”, is widely distributed in the South-East regions 
of  Tunisia (Bengardane, Benikdache, Djerba and Tataou-
ine). It is commonly used in traditional medicine for its 
antivenom, anti-inflammatory, antirheumatic, antimicro-
bial and antidiabetic properties10,11,8, probably due to the 
presence and the richness of  bioactive compounds such 
as flavonoids, chromones, acetophenones, coumarins and 
essential oils12-14. The most common parts used are leaves 
and flowers15. In addition to the traditional use, scientific 
researches about the antidiabetic effect of  A. campestris 
leaves extracts have been carried out using an experimen-
tal model of  diabetes induced in rats16,17. These studies 
demonstrated the antioxidant activity of  different types 
of  A. campestris leaf  extracts which were responsible of  
the improvement of  the functionality and regeneration 
of  pancreatic beta-cells. Moreover, beneficial effects in 
diabetic nephropathy, correction of  hyperlipidemia and 
prevention of  diabetic complications have been report-
ed16,17. However, to the best of  our knowledge, the hypo-
glycemic effect of  A. campestris leaf  extracts has not yet 
been investigated in different approaches, other than the 
diabetes induced rats model. Therefore, the present study 
aimed to evaluate the hypoglycemic action of  a fraction 
from a methanolic extract of  A. campestris leaves using in 
vivo (Oral Glucose Tolerance Test (OGTT))  and ex vivo 
(isolated perfused rat liver (IPRL)) methods.
Materials and methods
Plant collection and identification
A. campestris fresh leaves were collected in the region of  
Sidi Bouzid (Tunisia). The plant was identified and au-
thenticated by Prof. Ben Nasri Ayachi Mouhiba, Facul-
ty of  Science of  Tunis, University of  Tunis El Manar. 
Samples were cleaned, air-dried for several days at room 
temperature in a ventilated dark area for better preserving 
temperature and light sensitive molecules and powdered 
using an electric blender. The leaf  powder was used to 
prepare the methanolic extract.
Extraction and fractionation
A. campestris leaf  dry powder (225 g) was macerated in 
pure methanol (750 mL × 3) with continuous stirring. 
This operation was repeated three times with the renewal 
of  the solvent. Each maceration took 24h. Macerates were 
firstly filtered and then evaporated to dryness by a rotary 
evaporator at 40 °C. The dry residue was weighed to cal-
culate the extraction yield (52.54 g) and stored at 4 °C for 
later use. The dry methanolic crude extract was dissolved 
in a methanol (MeOH)/H2O mixture (10:90, v/v) and 
then subjected to a liquid-liquid partition with solvents of  
increasing polarities: hexane was used to remove lipophil-
ic pigments and residual fats (8.15 g), dichloromethane to 
separate the components with low polarity (11.65 g), ethyl 
acetate to extract the medium polar constituents (3.45 g) 
and n-butanol (n-BuOH) to obtain the polar compounds 
and the majority of  glycosides (11.61 g). The resulting 
fractions were concentrated to dryness under reduced 
pressure and weighed to determine the mass yield.
Animals
Swiss albinos mice (30 g) were used to assess acute tox-
icity. Wistar male rats weighing between 200 and 300 g 
were selected for the OGTT and the ex vivo experiments. 
Animals were obtained from Pasteur Institute of  Tunis 
(Tunisia). During the acclimatization period conducted 
in the animal house of  the Faculty of  Sciences of  Tunis 
and in standardized environmental conditions, rats were 
distributed in cages lined with wood chips, having free 
access to water and rodent pellet diet provided by the EL-
BADR company (Utica, Tunisia). Animals were treated in 
accordance with its guidelines and according to Medical 
Ethics Committee for the Care and Use of  Laboratory 
Animals of  the Pasteur Institute of  Tunis (approval num-
ber: FST/LNFP/Pro 152012).
Acute toxicity test
For acute toxicity study, Swiss albinos mice were used 
as described by Miller and Tainter18. Briefly, the method 
consisted of  oral administration of  BFACME at increas-
ing doses: 1000, 2000 and 3000 mg/kg body weight (BW) 
to 3 groups of  mice (4 mice / group). General toxicity 
signs and behavioral disorders were registered during 24 
hours.
Experimental protocol for in vivo hypoglycemic activ-
ity
Hypoglycemic effect in normal rats
To test the glucose-lowering activity of  the BFACME, a 
dose of  550 mg/kg BW was administered by gavage to 
normoglycemic rats, fasted for 16 hours with free access 
to water. Control group was treated with physiological sa-
line and reference group was treated with an oral antidi-
abetic agent (ADO) glibenclamide (10 mg/kg BW) (Da-
onil; Aventis Pharma), following the protocol described 
elsewhere19,20. Blood samples were drawn by puncture 
of  the tail vein. Fasting blood glucose level was estimat-
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ed first at t0 (just prior to administration of  drug and 
BFACME), then after 2h of  treatment. Serum glucose 
concentrations were measured by the glucose oxidase 
method using commercial reagent kit (Ref. 20 121) pur-
chased from Biomaghreb (Ariana Tunis, Tunisia). Percent 
decrease of  blood glucose level was calculated using the 
following equation:
Decrease % = ((blood glucose level before treatment – 
blood glucose level after treatment) / blood glucose level 
before treatment) × 100
Hypoglycemic effect in glucose induced hyperglyce-
mic rats (OGTT)
Twenty-four rats were divided into six groups (n=4) and 
treated by following the protocol described by N’doua et 
al.21. Four increasing doses of  BFACME were tested. Af-
ter an overnight fast (16 h), group 1 was treated as normal 
control group by receiving orally 10 mL/kg BW of  physi-
ological saline, group 2 (Reference) was treated orally with 
glibenclamide (10 mg/kg BW) (Daonil; Aventis Pharma) 
and groups 3 to 6 (treated groups) were treated with 100, 
250, 400 and 550 mg of  BFACME/kg BW, respectively. 
Glucose solution (4 g/kg BW22) was orally administered 
at first followed by drug or BFACME. Blood samples 
were drawn from tail vein at 0 min (just prior to glucose 
load and treatment), 30, 60, 90 and 120 min after glucose 
administration. Blood glucose concentrations were deter-
mined as above. Percent decrease of  blood glucose level 
after 120 min was measured using the following equation:
Decrease % = ((Blood glucose level after 30 min of  glu-
cose load ingestion – blood glucose level at t = 120 min) 
/ blood glucose level after 30 min of  glucose load inges-
tion) × 100
Hypoglycemic activity in IPRL model
Normal rat livers were isolated and perfused according 
to the technique developed by Gonzalez-Martin et al.23. 
Briefly, animals were, firstly, anesthetized with sodium 
pentobarbital (60 mg/kg BW). After midline laparoto-
my and injection of  200 IU of  heparin diluted in Krebs 
liquid, cannulas for the influent and effluent perfusates 
were applied to the portal vein and the inferior vena cava, 
respectively. After excision, liver was placed in a humid 
thermo-regulated chamber (37 °C) and immediately per-
fused in single-pass mode to ensure rinsing. Perfusions 
were conducted using an isotonic Krebs-Henseleit solu-
tion (KH, pH = 7.30, 37 °C) prepared as described pre-
viously24. The buffer was saturated with 95% O2 / 5% 
CO2. The perfusion fluid circulation was provided by a 
peristaltic pump at constant pressure and calibrated for 
a basal hepatic flow rate about 3 ml/min/g liver. In all 
experiments, livers were perfused for 120 min in a recir-
culating system in which the perfusate exited through the 
lower vena cave to return in a container before returning 
to the pump. Samples from liver effluent were collected 
every 10 min and subsequently frozen at -20 °C until glu-
cose assay. Perfusions were initiated with 6 mM glucose 
medium in order to equilibrate liver. After 30 min, livers 
were exposed to a high glucose concentration (30 mM). 
For each experimental condition, insulin (120 mUI/L) 
or/and BFACME were added to the perfusion liquid at t 
= 40 min. Concentrations of  glucose (30 mM) and insu-
lin were chosen to mimic postprandial conditions (while 
rat basal blood glucose is about 6 mM)24,25. Control per-
fusions were performed with either insulin (120 mUI/l) 
(negative control) or BFACME alone at the higher con-
centration (positive controls). Treatment groups were 
perfused with insulin and BFACME, added simultane-
ously in the perfusion medium. Three increasing doses 
of  BFACME were tested: 0.3, 0.5 and 0.7 mg/mL/g liver. 
Percent decrease of  effluent glucose level was measured 
using the following equation:
Decrease % = ((effluent glucose level at t = 40min – ef-
fluent glucose level at t = 120 min) / effluent glucose 
level at t = 40 min) × 100
Statistical analysis
Data analysis was performed using statistical program 
GRAPHPAD PRISM (version 6.00; GraphPad Software 
Inc., San Diego, CA, USA). Results were expressed as the 
mean ± standard deviation. For the test of  hypoglycemic 
effect in normal rats, results were statistically analyzed 
using Tow-way ANOVA followed by Sidak’s multiple 
comparison; Multiple t-test using Holm-Sidak method 
multiple comparison was used in the OGTT and ex vivo 
experiments. The values of  p<0.05, p<0.01 and p<0.001 
were considered as statistically significant.
Results
Acute toxicity of  BFACME
During the observation period, the BFACME adminis-
tered at doses less than or equal to 3000 mg/kg BW did 
not cause behavioral or physical changes characterized by 
symptoms such as diarrhea, convulsions and reduced mo-
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tor activity. As well, no mortality was observed during the 
test period. Thus, the LD50 value of  BFACME is greater 
than 3000 mg/kg BW.
Hypoglycemic effect in normal rats
As shown in figure 1, administration of  physiological sa-
line did not affect the basal blood glucose in normal rats 
after 2h of  study , while both doses of  BFACME and 
glibenclamide significantly reduced fasting blood glucose 
level (P<0.01 and P<0.001, respectively). The highest 
dose of  BFACME reduced blood glucose level by 37.3%, 
while the decrease by the reference drug was about 24.7%.
Hypoglycemic effect in glucose induced hyperglycemic 
rats (OGTT)
 
 Figure 1: Effect of BFACME at a dose of 550 mg/kg BW on fasting blood glucose level (g/L) in 
 normal rats. 
Values are presented in mean ± SD (n=4). BFACME: Butanol Fraction from Artemisia campestris 
 methanol extract. ** p<0.01 and *** p<0.001, glucose level before administration (t0) compared 
 to glucose level after administration (t 2h). Tow-way ANOVA followed by Sidak’s multiple comparison  
was performed to analyze this comparison. 
As shown in figure 2, the oral administration of  glucose 
(4 g/kg BW) in rats fasted for 16 h caused hyperglycemia 
30 min later. The administration of  glibenclamide (refer-
ence group) significantly reduced the hyperglycemic peak. 
Moreover, it had significant hypoglycemic effect at 60, 90 
and 120 min as compared to controls. Treatment with 
BFACME at doses of  400 and 550 mg/kg BW signifi-
cantly (p<0.05) decreased the hyperglycemic peak after 
30 min of  glucose load. Rats treated with lower doses of  
BFACME (100 and 250 mg/kg BW) showed no signifi-
cant change in glucose levels compared to control rats. 
Therefore, doses of  400 and 550 mg/kg BW are the most 
potent in mitigating hyperglycemia induced by glucose 
load. At the highest dose tested, the BFACME reduced 
blood glucose level by 29.5%, while the decrease by the 
reference drug was about 22.7% (t = 120 min).
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Figure 2: Effect of BFACME on glucose induced hyperglycemia (g/L) in normal rats. 
Each point represents mean ± SD (n = 4), glucose level at a time (min) of treatment. Glucose load was administered at t0 min  
followed by reference drug or BFACME.  Glibenclamide: glibenclamide (10 mg/kg BW); Tr 100 mg/kg: group treated with  
BFACME  
100 mg/kg BW dose; Tr 250 mg/kg: group treated with BFACME 250 mg/kg BW dose; Tr 400 mg/kg: group treated with  
BFACME 400 mg/kg BW dose; Tr 550 mg/kg: group treated with BFACME 550 mg/kg BW dose. * p <0.05, ♣ p<0.05 and 
 # p<0.05, Controls vs Tr 550 mg/kg BW, Tr 400 mg/kg BW and Glibenclamide, respectively. Multiple t-tests were performed 
 to analyze results using the Holm-Sidak method multiple comparison. 
Hypoglycemic effect in IPRL model
In the negative controls, the introduction of  insulin after 
increasing the glucose concentration to 30 mM induced 
a significant (p< 0.05) gradual decline in glucose levels 
when compared to positive control group, indicating an 
activation of  glycogen synthesis (figure 3). After 30 min 
of  BFACME and insulin addition, the glucose concen-
tration in the effluent decreased significantly (p< 0.05) 
compared to the negative controls. The highest doses of  
BFACME (0.5 mg/mL/g liver and 0.7 mg/mL/g liver) 
lead to glucose concentration at basal level as early as 90 
min, while the lowest dose (0.3 mg/mL/g liver) does not 
restore this concentration even to t = 120min. In the pres-
ence of  insulin, BFACME at the highest dose (0.7 mg/
mL /g liver) reduced the glucose level of  the effluent by 
58.5%, while the decrease observed only in the presence 
of  insulin (negative control) was about 40.5%. On the 
other hand, the addition of  BFACME at the highest dose 
and in the absence of  insulin did not cause any change on 
glucose level as compared to positive controls.
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Figure 3: Effect of BFACME on the reactivity of isolated perfused rat liver to increasing glucose concentration (6 to 30 mM) when perfused  
in recirculation mode). 
Each point represents mean ± SD (n = 4), glucose level at a time (min) of perfusion. Glucose was added at 30 min of perfusion and Insulin 
or/and BFACME was added at 40 min of perfusion. Controls (insulin): perfusion only in the presence of insulin (Negative control group); Tr 0,7 
mg/mL/g: group treated with BFACME at 0,7 mg/mL/g liver in the presence of insulin; Tr 0,5 mg/mL/g: group treated with BFACME at 0,5 
mg/mL/g liver in the presence of insulin; Tr 0,3 mg/mL/g: group treated with BFACME at 0,3 mg/mL/g liver in the presence of insulin; Tr with 
BFACME (in absence of insulin): treatment only with the BFACME at the higher dose 0,7 mg/mL/g liver in the absence of insulin (positive 
control group). * p <0.05, ♣ p<0.05, ♠ p<0.05 and ♦ p<0.05, Negative controls vs Tr 0.7 mg/mL/g liver, Tr 0.5 mg/mL/g liver, Tr 0.3 
mg/mL/g liver and positive controls, respectively. Multiple t-tests were performed to analyze results using the Holm-Sidak method multiple 
comparison. 
  Discussion
Herbal medicine has become nowadays an alternative 
therapy in diabetes because of  the greatly increased dis-
covery of  potent plant extracts and pharmacologically ac-
tive compounds that played critical roles in modern drug 
development26. A. campestris  is one of  the enormous plant 
heritages in North Africa, traditionally used for its many 
health benefits. Sefi et al.16,17 have shown the effect of  an 
A. campestris  leaf  extract against oxidative stress associ-
ated with diabetes and its resulting complications on an 
animal model of  induced diabetes. However, the hypo-
glycemic effects of  that species have not been examined 
in other ways. So, our study mainly aimed at providing a 
new exploratory approach not only for the in vivo anti-hy-
perglycemic activity assay using the OGTT, but also for 
the ex vivo study of  the hypoglycemic effect of  BFACME 
using the IPRL as a model. Glucose tolerance test is gen-
erally used to assess the ability of  the body to metabo-
lize glucose because it detects changes in post-prandial 
glucose concentration that usually occur before fasting 
glucose changes. OGTT can be used to diagnose diabetes 
mellitus or insulin resistance27. In other hand, we chose 
as reference molecule the glibenclamide, an oral sulfo-
nylurea antidiabetic drug to explore the effect generated 
by the use of  BFACME. After 30 min of  oral glucose 
load administration (4 g/kg of  BW), a marked increase 
in blood sugar levelsin rats was recorded, treatment with 
BFACME at doses of  400 and 550 mg/kg BW signifi-
cantly reduced the hyperglycemic peak comparatively to 
control group. When compared to the glibenclamide, the 
administration of  BFACME (550 mg/kg BW) decreased 
glycaemia by 6.8% as more as that obtained with the stan-
dard drug at t = 120 min. From these results, BFACME 
appears to be able to reduce post-prandial hyperglycemia 
by an ADO mimetic effect. Indeed, ADOs are classi-
fied into four categories: sulfonylureas, biguanides, glita-
zones and alpha-glucosidase inhibitors, acting on several 
targets i.e stimulation of  insulin secretion by pancreatic 
cells, improvement of  insulin sensitivity or by inhibiting 
α-glucosidase which is a key enzyme catalyzing the final 
step in the carbohydrate digestion process28. The IPRL 
model has provided the opportunity to study the impact 
of  BFACME on hepatic glucose metabolism. Indeed, the 
perfusion of  the liver in a closed-circuit mode aims at 
approaching the in vivo conditions; it could be used as a 
model in kinetic studies to evaluate the impact of  tested 
substances on liver function when non-hepatic compart-
ments are excluded24. Following introduction of  insulin 
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in the perfusion medium, a significant decline in glucose 
level in the efferent liquid was noted from the 80th min 
when compared to positive control group. These results 
presented in figure 3 are in agreement with those of  Bail-
let-Blanco et al.24 who suggest that in the isolated perfused 
liver of  normally fed rats, there is a net flow of  glycogen 
synthesis in the presence of  glucose at high concentra-
tions (30 mM). The decrease of  glucose levels after ad-
dition of  insulin was significantly amplified by BFACME 
addition (18% of  decrease), mainly at the highest dose 
(0.7 mg/mL/g liver). However, this hypoglycemic effect 
of  BFACME was observed only when insulin was pres-
ent in the perfusion medium. Thus, it could be speculated 
that the BFACME enhances the role of  insulin by acting 
at different levels such as improvement of  hepatic insulin 
sensitivity or stimulation of  insulin signaling pathways in 
liver29. Results obtained in the ex vivo model corroborate 
those demonstrated in the in vivo approach and confirm 
the hypoglycemic potential of  BFACME which could be 
proposed as useful preparation for the glycaemia regula-
tion in the manner of  the antidiabetic oral drugs.  Chem-
ical characterization of  BFACME should be conducted 
to relate the observed effect to an active principle. Data 
from literature have reported that phytochemical screen-
ing of  A. campestris  have pointed a richness of  bioactive 
molecules notably phenolic compounds, flavonoids, gly-
cosides and essential oils which have been associated to 
several biological activities such as a strong antioxidant 
potential and hypoglycemic properties14,30-32. Phenolics 
such as rutin, quinic acid, chlorogenic acid and caffeic 
acids have been characterized in Artemisia campestris14 and 
other species of  the genus Artemisia25,33,34.
Conclusion
Results presented in this paper indicated clearly that the 
BFACME is dotted with an insulin-potentiating effect; 
an ADO-like effect was observed since the insulin ac-
tion was exacerbated in the presence of  BFACME. The 
chemical characterization of  the used fraction is needed 
to define the active principle and pharmacokinetic studies 
might be conducted to determine some parameters such 
as the effectiveness dose to be used and the clearance of  
the active substance.
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